- BRADYKININ
- Bradykinin acetate
- Bradykinin, 6-L-threonine-
- Bradykinin,N2-(L-isoleucyl-L-seryl)-
- 58822-25-61-5-b-Neoendorphin (human) (9CI)
- 58822-47-22H-Pyran-4-acetic acid,3-ethenyl-2-(b-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-,(2S,3R,4S)-
- 58823-88-4(Carboxylatomethyl)trimethylammonium phosphate
- 58823-93-11,2,3-Propanetricarboxylicacid, 1-oxo-, barium salt (1:?)
- 5882-44-0Benzenamine,N,N-dimethyl-, hydrochloride (1:1)
- 588-30-72-Propenoic acid,3-(3-hydroxyphenyl)-
- 58832-36-33-Furancarboxylic acid, 5-bromo-
- 588-32-9Acetic acid,2-(3-chlorophenoxy)-
- 588-36-35-Pyrimidinemethanol,4-amino-2-(methylthio)-
- 58840-79-2D-Lysine, N2-acetyl-
Hot Products
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
- 7631-86-9Silicon dioxide
- 302-79-4Tretinoin
- 77-92-9Citric acid
|
Basic Information |
|
Post buying leads |
|
Suppliers |
|
Cas Database |
| Name |
BRADYKININ |
EINECS | 227-781-2 |
| CAS No. | 58-82-2 | Density | 1.49 g/cm3 |
| PSA | 413.78000 | LogP | 1.28130 |
| Solubility | H2O: >40 mg/mL | Melting Point |
170ºC |
| Formula | C50H73 N15 O11 | Boiling Point | °Cat760mmHg |
| Molecular Weight | 1060.22 | Flash Point | °C |
| Transport Information | N/A | Appearance | N/A |
| Safety | Experimental teratogenic and reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx. | Risk Codes | N/A |
| Molecular Structure |
|
Hazard Symbols | N/A |
| Synonyms |
Arginine,N2-[N-[1-[N-[N-[N-[1-(1-arginyl-L-prolyl)-L-prolyl]glycyl]-3-phenylalanyl]seryl]prolyl]-3-phenylalanyl]-(6CI); 1020: PN: EP2071336 PAGE: 73 unclaimed sequence; 1021: PN: WO2006091861SEQID: 1021 claimed protein; 107: PN: WO2006069765 SEQID: 107 claimed protein;10: PN: WO2008008766 SEQID: 124 unclaimed sequence; 111: PN: WO2008058016SEQID: 112 claimed protein; 115: PN: WO2008104000 TABLE: 4 unclaimed sequence;11: PN: US20040209344 SEQID: 7 unclaimed protein; 13: PN: WO0023092 SEQID: 13unclaimed protein; 147: PN: US20030119021 SEQID: 25 unclaimed protein; 14: PN:US20090088553 SEQID: 88 unclaimed protein; 14: PN: US6525021 SEQID: 13unclaimed protein; 153: PN: WO2006067198 SEQID: 165 claimed protein; 156: PN:WO2009126292 TABLE: 4 unclaimed sequence; 15: PN: US6258776 SEQID: 24 unclaimedprotein; 15: PN: WO2007058336 SEQID: 15 claimed sequence; 165: PN:US20050175581 SEQID: 165 unclaimed protein; 16: PN: WO2006079099 SEQID: 1unclaimed protein; 175: PN: WO2008008805 SEQID: 178 unclaimed protein; 187: PN:US20030176421 PAGE: 54-55 claimed protein; 18: PN: JP2006280210 SEQID: 18unclaimed protein; 19: PN: US20060223140 SEQID: 18 claimed protein; 19: PN:WO2007022248 SEQID: 19 claimed protein; 1: PN: CN101344527 PAGE: 6 claimedsequence; 1: PN: JP2005049164 SEQID: 1 claimed protein; 1: PN: US20040198666SEQID: 1 unclaimed protein; 1: PN: US20040220110 PAGE: 2 unclaimed protein; 1:PN: US20070015715 SEQID: 1 unclaimed sequence; 1: PN: US7605120 SEQID: 1unclaimed sequence; 1: PN: WO02102835 SEQID: 3 unclaimed protein; 1: PN:WO2006130718 SEQID: 1 unclaimed protein; 1: PN: WO2006134125 SEQID: 22 claimedprotein; 227: PN: WO2009118205 PAGE: 176 unclaimed sequence; 229: PN:US20090048431 SEQID: 227 claimed sequence; 24: PN: US20080226503 TABLE: 1unclaimed sequence; 2: PN: WO2005042027 SEQID: 1 unclaimed protein; 2: PN:WO2005057221 PAGE: 17 unclaimed protein; 360: PN: WO2009117524 SEQID: 5unclaimed sequence; 38: PN: WO2006017688 SEQID: 38 unclaimed protein; |
Article Data | 9 |
BRADYKININ Chemical Properties
Molecular Formula: C50H73N15O11
Molar mass: 1060.21 g/mol
EINECS: 227-781-2
Density: 1.49 g/cm3
Index of Refraction: 1.693
Storage temp: −20°C
Solubility: H2O: >40 mg/mL
Structure of Bradykinin (58-82-2):
BRADYKININ History
Bradykinin (58-82-2) was discovered in 1948 by three Brazilian physiologists and pharmacologists working at the Instituto Biológico, in São Paulo, Brazil.The discovery was part of a continuing study on circulatory shock and proteolytic enzymes related to the toxicology of snake bites, started by Rocha e Silva as early as 1939.they discovered the powerful hypotensive effects of bradykinin in animal preparations. It was detected in the blood plasma of animals after the addition of venom extracted from the Bothrops jararaca, brought by Rosenfeld from the Butantan Institute. Bradykinin was to prove a new autopharmacological principle, i.e., a substance that is released in the body by a metabolic modification from precursors. According to B.J. Hagwood, Rocha e Silva's biographer, "The discovery of bradykinin has led to a new understanding of many physiological and pathological phenomena including circulatory shock induced by venoms and toxins."
BRADYKININ Production
The kinin-kallikrein system makes Bradykinin (58-82-2) by proteolytic cleavage of its kininogen precursor, high-molecular-weight kininogen, by the enzyme kallikrein.
BRADYKININ Toxicity Data With Reference
| 1. | cyt-mus:emb 500 µg/L | DANKAS Doklady Akademii Nauk S.S.S.R. 282 (1985),173. |
BRADYKININ Safety Profile
Experimental teratogenic and reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx.
Safety Statements:
22: Do not breathe dust
24: Avoid contact with skin
25: Avoid contact with eyes
BRADYKININ Specification
Bradykinin (58-82-2) also can be Synthetic bradykinin .And it is a peptide that could cause blood pressure to lower.It is a physiologically and pharmacologically active peptide of the kinin group of proteins, consisting of nine amino acids.As a class of drugs called ACE inhibitors, which are used to lower blood pressure, increase bradykinin further lowering blood pressure. Bradykinin works on blood vessels through the release of prostacyclin, nitric oxide, and Endothelium-Derived Hyperpolarizing Factor.
What can I do for you?
Get Best Price
